Independent Study Highlights Robustness and Ease-of-Use of Truvian’s Blood Testing Platform in a Real-World Clinical Setting
July 30 2024 - 10:30AM
Business Wire
Results presented at the Association for
Diagnostics and Laboratory Medicine (ADLM) 2024 meeting in Chicago
on July 30, 2024
Truvian expands expert Clinical Advisory Board
to accelerate the transformation of primary care
Researchers from University of California San Diego School of
Medicine will be providing the latest evidence from a recent
evaluation of Truvian Health’s (Truvian’s) multi-modal blood
testing platform at the Association for Diagnostics and Laboratory
Medicine (ADLM) meeting in Chicago this week. Their findings
support a growing body of evidence that suggests the future of
routine blood testing will be defined by automated, benchtop
systems that provide decentralized diagnostics anywhere you go. The
independent study (titled “Advancing Point-of-Care Testing:
Independent Evaluation of the Truvian Platform”) focused on
comparing the performance of Truvian's blood testing device to
FDA-cleared devices found in central laboratories. Findings show
the accuracy of Truvian’s device is highly comparable to
centralized testing and demonstrates a high degree of
reliability.
Currently, routine blood testing is performed by skilled
technicians in centralized labs which delays turnaround times,
increases costs, and remains burdensome for patients and providers
alike, leading to poor adherence and potential delayed medical
intervention. Truvian’s platform has the ability to address these
shortcomings by providing patients and providers with comprehensive
blood testing at the point-of-care. Following its clearance by the
FDA, the device can be placed in physician offices, clinics,
pharmacies, and long-term care facilities where samples can be run
by non-laboratorians.
“With each Truvian milestone, healthcare providers and patients
move closer to a world where they can make informed decisions about
their health," said Dena Marrinucci, Ph.D., Co-Founder and Chief
Operating Officer of Truvian. "The positive findings from this
independent study reinforce our confidence that the accuracy and
consistency of our platform can make it possible to access central
laboratory quality results anywhere you go.”
Samples from patients with a wide range of chronic illnesses
were evaluated on the Truvian platform. The results produced from
untrained operators using the Truvian platform were concordant with
testing performed in the central laboratories by qualified medical
staff. Truvian’s platform demonstrated a run reliability of 98% and
its user interface was described by 100% of operators as “easy to
follow.”
“The data from our independent evaluation showed the platform’s
robust concordance to comparator devices, indicating its
performance, usability and suitability in various clinical
settings,” said Dr. Susan Little, director of the AntiViral
Research Center (AVRC) at UC San Diego School of Medicine and
principal investigator of the study.
To continue its efforts in redefining the future of blood
diagnostics, Truvian recently expanded its Clinical Advisory Board
with the additions of Dr. Karim Vellani, Chief Medical Officer of
Shoppers Drug Mart in Canada, and Dr. Jennifer Peña, FACP, AAHIVS,
who served as a physician in the White House Medical Unit over two
administrations and is both the Founder and Owner of Medicina
Exclusiva, Puerto Rico's top executive and concierge medicine
consulting firm. Truvian’s Clinical Advisory Board is comprised of
renowned clinicians with deep experience in patient-provider
relationships who will help enable transparent, evidence-based
adoption of blood testing across the globe.
“The results of a pilot through Shoppers Drug Mart were similar
to that of the UC San Diego study – that Truvian’s comprehensive
blood testing solution has the ability to make blood testing more
convenient and accessible to patients,” said Dr. Vellani. “I’m
honored to join Truvian’s Clinical Advisory Board and look forward
to working with the team leading innovation in blood testing.”
“This independent study provides strong external validation of
the fact that Truvian's multi-modal platform can achieve clinical
performance equivalent to the central laboratory across a large
panel of tests with a single sample,” added Dr. Peña. “The ability
to improve quality of care and patient outcomes for people around
the world is critical, especially in locations like my homeland of
Puerto Rico that faces many challenges to its healthcare system.
Collaborating with Dr. Vellani, the Clinical Advisory Board, and
the Truvian team to fulfill their mission aligns with my personal
and professional purpose.”
For more details on the UC San Diego School of Medicine study
and its findings, visit the ADLM poster presentation (abstract #
A-323) on July 30th, from 9:30 AM to 5:00 PM Central Time. The
poster will be presented as part of the “Point-of-Care Testing”
session.
Stop by and learn more about Truvian and see a demo at the ADLM
Expo, Booth 3055.
About Truvian
Truvian is a transformational healthcare company bringing
lab-accurate results anywhere you go, enabling patients to engage
healthcare providers and lead healthier lives. With a focus on
making routine blood testing accessible, convenient and
transparent, Truvian is accelerating the transition to a
sustainable healthcare ecosystem through its comprehensive benchtop
solution that delivers timely, actionable results to help stop
disease before it starts. For more information, visit
truvianhealth.com or follow us on LinkedIn and X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730340205/en/
Steve Atkinson Spectrum Science (858) 519-2224
satkinson@spectrumscience.com